🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jingsong Zhang

Anhui Medical University

ORCID: 0000-0003-1192-5116

Also affiliated with Moffitt Cancer Center, First Affiliated Hospital of Anhui Medical University

MedicineBiochemistry, Genetics and Molecular BiologyMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer”.

Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer

International Journal of Molecular Sciences(2023)10.3390/ijms24031830

N/A

0.500DataRank · unranked

27 citations

Yijun Tian, Paul Allen Stewart, Yury O. Núñez López, Brandon J. Manley, Bruna Pellini +9 more

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00813-3

N/A

0.241DataRank · unranked

4 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5523

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +9 more

Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics

Neoplasia(2021)10.1016/j.neo.2021.06.013

N/A

0DataRank · unranked

45 citations

Jingsong Zhang, Tian Zhang, Andrew Z. Wang, Robert J. Butler, Robert A. Gatenby +2 more

Multidisciplinary analysis of evolution based Abiraterone treatment for metastatic castrate resistant prostate cancer

medRxiv(2021)10.1101/2021.11.30.21267059

N/A

0DataRank · unranked

2 citations

Jessica J. Cunningham, Joel S. Brown, Robert A. Gatenby, Jingsong Zhang

Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps595

N/A

0DataRank · unranked

12 citations

Youngchul Kim, Jennifer Rembisz, Richard Piekarz, Timothy W. Synold, Jingsong Zhang +2 more

Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4574

N/A

0DataRank · unranked

3 citations

Philippe E. Spiess, Wade J. Sexton, Scott M. Gilbert, Michael Poch, Julio M. Pow‐Sang +11 more

Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5071

N/A

0DataRank · unranked

2 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

European Urology(2023)10.1016/j.eururo.2023.03.036

N/A

0DataRank · unranked

10 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +11 more

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5074

N/A

0DataRank · unranked

2 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Yeonjung Jo, Andrea Harzstark +15 more

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5048

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0400

N/A

0DataRank · unranked

34 citations

Melissa A. Reimers, Chamila Perera, Wassim Abida, Jonathan Chou, Felix Y. Feng +17 more

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

European Urology Oncology(2024)10.1016/j.euo.2024.03.001

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo +17 more

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation

Nature Communications(2020)10.1038/s41467-020-15424-4

N/A

0DataRank · unranked

106 citations

John D. Nagy, Travis Gerke, Tian Zhang, Andrew Z. Wang, Jingsong Zhang +3 more

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects

Cancer Discovery(2025)10.1158/2159-8290.cd-24-1500

N/A

0DataRank · unranked

6 citations

David S.P. Tan, Anastasios Stathis, Geoffrey I. Shapiro, Satoru Iwasa, Markus Joerger +17 more

Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.111

N/A

0DataRank · unranked

6 citations

Rana R. McKay, Mary‐Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman +14 more